Pharmacy, Hospital Reina Sofia. Navarre Health Service, Tudela, Spain.
Pharmacy Management Service, Navarre Health Service, Pamplona, Spain
Eur J Hosp Pharm. 2021 Jan;28(1):50-52. doi: 10.1136/ejhpharm-2019-002016. Epub 2019 Oct 3.
A possible case of ulcerative colitis (UC) developed during treatment with ixekizumab is reported. Ixekizumab is a human monoclonal antibody approved for chronic plaque psoriasis that works by blocking interleukin-17 (IL-17). Cytoquines, such as IL-17, may be involved in the pathophysiology of psoriasis and inflammatory bowel diseases. We describe the case of a 76-year-old woman who presented with an episode of acute self-limited colitis after receiving ten doses of ixekizumab. It was resolved after treatment withdrawal. A re-challenge was done after 3 months and symptoms returned. Colonoscopy results confirmed the diagnosis of UC. Symptoms remitted after drug discontinuation and treatment with corticosteroids. Four months after stopping ixekizumab, she remains asymptomatic and she is being treated with guselkumab with adequate response. The Naranjo algorithm revealed a probable causal relationship.This adverse event should be taken into account by physicians and pharmacists before prescribing or reviewing therapies in order to improve patients' safety.
现报道一例在接受依奇珠单抗治疗期间发生溃疡性结肠炎（UC）的可能病例。依奇珠单抗是一种人源化单克隆抗体，获批用于治疗慢性斑块型银屑病，其作用机制为阻断白细胞介素-17（IL-17）。细胞因子，如 IL-17，可能参与银屑病和炎症性肠病的病理生理学过程。我们描述了一例 76 岁女性的病例，她在接受十剂依奇珠单抗治疗后出现急性自限性结肠炎发作。停药后得到缓解。3 个月后再次进行药物挑战，症状再次出现。结肠镜检查结果证实了 UC 的诊断。停药和皮质类固醇治疗后症状缓解。停止使用依奇珠单抗后 4 个月，她无症状，目前正在接受 Guselkumab 治疗，反应良好。Naranjo 算法提示可能存在因果关系。在开具或审查治疗方案之前，医生和药剂师应考虑到这一不良事件，以提高患者安全性。
